Recombinant FSH (follitropin alpha)
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ovulation Induction
Conditions
Ovulation Induction
Trial Timeline
Mar 1, 2009 → Mar 1, 2011
NCT ID
NCT01081626About Recombinant FSH (follitropin alpha)
Recombinant FSH (follitropin alpha) is a approved stage product being developed by Merck for Ovulation Induction. The current trial status is completed. This product is registered under clinical trial identifier NCT01081626. Target conditions include Ovulation Induction.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01081626 | Approved | Completed |
Competing Products
13 competing products in Ovulation Induction